AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34544754
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of erector spinae block and retrolaminar block (10 mL each)
Trial: 34544754
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae block (20 mL)
Trial: 36243227
Drug: Direct consultations
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct consultations with medical physicists during treatment simulation and before the first treatment.
Trial: 35990583
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg twice daily by mouth in 21-day cycles)
Trial: 34983471
Drug: Viscosupplementation (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscosupplementation (single-dose intraarticular hyaluronic acid injection)
Trial: 32037273
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg of methylprednisolone
Trial: 32134035
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no surface treatment)
Trial: 37062349
Drug: PAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP therapy with lifestyle counseling
Trial: 36480147
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral ticagrelor 180 mg
Trial: 36480147
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin 300 mg plus ticagrelor 180 mg
Trial: 36480147
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine acetylsalicylate (LA)
Trial: 38648030
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin
Trial: 32571870
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 or 300 mg, every 4 or 8 weeks during a 72-week period
Trial: 35001562
Drug: No beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blockers (Control)
Trial: 32492682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EBUS-SE (<115) with size (<8 mm) and FDG-PET information
Trial: 32492682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of size and SE
Trial: 32245307
Drug: Guluronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guluronic acid (G2013) administered orally at a dose of 500 mg twice daily for 12 weeks
Trial: 34101934
Drug: NEPA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA plus single-dose DEX (12 mg on day 1) with no further DEX (DEX1)
Trial: 34101934
Drug: NEPA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA plus single-dose DEX (12 mg on day 1) with oral DEX (4 mg daily) on days 2-3 (DEX3)
Trial: 34101934
Drug: DEX (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (4 mg twice daily) on days 2-4 (DEX4)
Trial: 34990999
Drug: rTMS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rTMS intervention (20 daily sessions, 900 pulses per day for 4 weeks)
Trial: 34091568
Drug: Nurse-led cognitive
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led cognitive behavioral therapy intervention
Trial: 38042167
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (LDCT) screening
Trial: 33982473
Drug: Certain herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certain herbal preparation for the treatment of non-severe influenza
Trial: 33982473
Drug: Internationally recognized
RxNorm normalized name: Melanoma antigen recognized by T-cells 1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internationally recognized positive drugs or guidelines
Trial: 33420076
Drug: Biological network
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological network
Trial: 36432409
Drug: Fiber supplement
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplement
Trial: 38988455
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy
Trial: 32811575
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy with SSRIs
Trial: 34755287
Drug: Quxie Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quxie Capsule combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Trial: 34755287
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Trial: 34755287
Drug: Quxie Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quxie Capsule in subgroup analysis (⩾second-line therapy, non-targeted therapy, RAS gene wild type, left-sided colon)
Trial: 33367924
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 2,000 impulses
Trial: 33367924
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 4,000 impulses
Trial: 33367924
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 2,000 impulses
Trial: 33367924
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 4,000 impulses
Trial: 35181928
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment for overactive bladder
Trial: 34114250
Drug: Active MDMA
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active MDMA (75-125 mg)
Trial: 34114250
Drug: Placebo/control MDMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/control MDMA (0-40 mg)
Trial: 32195928
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents (not specified)
Trial: 34380382
Drug: 1100 mg
RxNorm normalized name: mineral oil 1100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 mg coffee berry extract
Trial: 34380382
Drug: 1100 mg
RxNorm normalized name: mineral oil 1100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 mg coffee berry extract plus 275 mg apple extract
Trial: 34380382
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg coffee berry extract plus 275 mg apple extract
Trial: 35649228
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion pump (HAIP) chemotherapy
Trial: 35649228
Drug: Drug‐eluting beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug‐eluting beads coated with irinotecan transarterial chemoembolization
Trial: 38842955
Drug: Sacral neuromodulation
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral neuromodulation (SNM) therapy
Trial: 33035097
Drug: SNM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNM therapy options
Trial: 34544939
Drug: Intravenous Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Itraconazole 200 mg
Trial: 34544939
Drug: Liposomal Amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal Amphotericin B 3.0 mg/kg once daily
Trial: 32053522
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous tranexamic acid (TXA) - 3 doses of 1,000 mg
Trial: 32053522
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 3 doses of intravenous normal saline solution
Trial: 32053522
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous tranexamic acid (TXA)
Trial: 32053522
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - intravenous normal saline solution
Trial: 35945094
Drug: a‐tDCS 1‐s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a‐tDCS 1‐s Group (one daily a‐tDCS session)
Trial: 35945094
Drug: a‐tDCS 2‐s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a‐tDCS 2‐s Group (two daily a‐tDCS sessions)
Trial: 35945094
Drug: Group SHAM
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group SHAM (one daily session with simulated current)
Trial: 35867804
Drug: istaroxime 1.0–1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: istaroxime 1.0–1.5 μg/kg/min
Trial: 32827729
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg subcutaneously once at baseline
Trial: 35762581
Drug: DAPT with
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT with cilostazol plus aspirin or clopidogrel
Trial: 32481297
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment in addition to basic treatment for sepsis
Trial: 32481297
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment for sepsis (Control group)
Trial: 35985506
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metformin and Testosterone
Trial: 36128795
Drug: Crono S-PID-50
RxNorm normalized name: PID
DrugBank: Phenindione (DB00498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crono S-PID-50 infusion pump (CP)
Trial: 33546534
Drug: Intra-dermal Platelet
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-dermal Platelet Rich Plasma (PRP) 1 ml monthly for 3 months
Trial: 33546534
Drug: 50% Trichloracetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% Trichloracetic Acid (TCA) applied by CROSS technique monthly for 3 months
Trial: 34550034
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg orally once daily
Trial: 34550034
Drug: Enoxaparin 4000
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 4000 AxaIU (0.4 mL) subcutaneously once daily
Trial: 33038432
Drug: Emricasan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emricasan (both doses)
Trial: 35241779
Drug: Mirtazapine (7.5–45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (7.5–45 mg/day)
Trial: 35831082
Drug: CLEAN Meds
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLEAN Meds intervention (short list of essential medicines)
Trial: 33300880
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment on the intervention side (axilla or groin)
Trial: 33300880
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment on the intervention side
Trial: 35337672
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with counseling sessions post-treatment
Trial: 32878899
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of tranexamic acid
Trial: 32878899
Drug: Severe TBI
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe TBI treatment with tranexamic acid
Trial: 35576873
Drug: Magnesium +
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium + Vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily)
Trial: 35576873
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D only (VitD; 1000 IU vitamin D 3 × daily)
Trial: 35172779
Drug: ADT combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT combined with modified docetaxel chemotherapy (docetaxel 40 mg/m2 on the 1st day and 35 mg/m2 on the 8th day, repeated every 21 days)
Trial: 35172779
Drug: ADT combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT combined with modified docetaxel chemotherapy
Trial: 35172779
Drug: ADT combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT combined with standard docetaxel chemotherapy
Trial: 34173659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GM EIA and BDG assay
Trial: 35486948
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (MP) in combination with transdermal estradiol (t‐E2)
Trial: 35486948
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) in combination with transdermal estradiol (t‐E2)
Trial: 35040887
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor (ticagrelor or clopidogrel) plus therapeutic dose of heparin (n=293)
Trial: 35040887
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of heparin only (usual care) (n=269)
Trial: 34344399
Drug: Sapropterin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin at 10 mg/kg/day (increased up to 20 mg/kg/day) plus Phe-restricted diet in the 'sapropterin extension' group (n = 26)
Trial: 32157182
Drug: Corneal stromal
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal stromal pocket irrigation with balanced salt solution
Trial: 39706666
Drug: TdaP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TdaP vaccine
Trial: 39706666
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine
Trial: 35572853
Drug: LT4 monotherapy
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 monotherapy
Trial: 33545954
Drug: Acoustic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic therapy combined with acupuncture
Trial: 36036106
Drug: Intranasal acupuncture
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal acupuncture
Trial: 36617611
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (budesonide nasal spray and loratadine)
Trial: 32919848
Drug: Topical Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Vancomycin Powder and Dilute Povidone-Iodine Lavage (VIP)
Trial: 35732183
Drug: Intervention providing
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention providing appointment and referral opportunity to community therapy
Trial: 35732183
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (Intervention + TAU)
Trial: 34506827
Drug: Genotype-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided treatment with ticagrelor for carriers of CYP2C19 loss-of-function alleles and clopidogrel for noncarriers.
Trial: 34506827
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with clopidogrel.
Trial: 33449510
Drug: Hypnotic suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestion (HS)
Trial: 34081560
Drug: Methylphenidate extended-release
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODT) 20 mg daily, adjusted weekly by 10-20 mg during a 4-week dose-optimization period.
Trial: 34795121
Drug: epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidermal growth factor receptor‐tyrosine kinase inhibitors
Trial: 34795121
Drug: cytotoxic chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cytotoxic chemotherapeutic agents
Trial: 34795121
Drug: immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune checkpoint inhibitors
Trial: 34075841
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Ellagic Acid (100 mg) plus Annona Muricata (100 mg), daily for 6 months
Trial: 32475446
Drug: Star anise
RxNorm normalized name: STAR ANISE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Star anise oil (SAO) supplementation at 400 mg/kg
Trial: 32475446
Drug: Star anise
RxNorm normalized name: STAR ANISE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Star anise oil (SAO) supplementation at 200 mg/kg
Trial: 32475446
Drug: Star anise
RxNorm normalized name: STAR ANISE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Star anise oil (SAO) supplementation at 600 mg/kg
Trial: 32475446
Drug: Star anise
RxNorm normalized name: STAR ANISE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Star anise oil (SAO) supplementation at 0 mg/kg (control)
Trial: 36862239
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg dexamethasone daily
Trial: 36862239
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg dexamethasone daily
Trial: 33148620
Drug: FOLFOXIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 3200 mg/m2)
Trial: 33148620
Drug: FOLFOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX plus bevacizumab (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 then 2400 mg/m2)
Trial: 33308359
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid daily)
Trial: 33308359
Drug: Enalapril only
RxNorm normalized name: Enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril only (10 mg daily)
Trial: 36244527
Drug: Gabapentin (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1800 mg/day)
Trial: 33251687
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection technique targeting the supraperiosteal plane
Trial: 33251687
Drug: Superficial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial injection technique in the superficial fatty layer
Trial: 33371123
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with conventional treatment (treatment A) for 6 weeks
Trial: 33371123
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (treatment C) for 6 weeks